Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

420
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
420
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

1.5K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.5K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

15.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
15.6K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

2.1K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.1K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

750
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
750
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

490
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
490

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do We Really Care About Our Children's School Safety? The Proof Is in the Pudding.

WMJ : official publication of the State Medical Society of Wisconsin·2026
Same author

Can You Properly Manage Delusional Parasitosis?

Innovations in clinical neuroscience·2025
Same author

Resurgence of polio and the path to eradication.

Tropical medicine & international health : TM & IH·2025
Same author

Babesiosis - An Unseen Epidemic.

WMJ : official publication of the State Medical Society of Wisconsin·2025
Same author

When Suicidality Is Suspected.

Southern medical journal·2025
Same author

Firearm Shootings: A Serious Public Health Issue.

Southern medical journal·2025

Related Experiment Video

Updated: Dec 11, 2025

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

2.8K

CGRP Inhibitors for Migraine.

Diksha Mohanty1, Steven Lippmann1

  • 1Dr. Mohanty is a Neurology Resident Physician, and Dr. Lippmann is a Psychiatry Emeritus Professor at the University of Louisville School of Medicine in Louisville, Kentucky.

Innovations in Clinical Neuroscience
|August 18, 2020
PubMed
Summary
This summary is machine-generated.

Migraine headaches affect many, with limited success from current treatments. New calcitonin gene-related peptide (CGRP) inhibitor drugs offer hope for improved migraine relief.

Keywords:
CGRP inhibitorMigrainecalcitonin-gene related peptidechronic migraineepisodic migraineerenumabgepantsheadachemonoclonal antibody

More Related Videos

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.2K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.1K

Related Experiment Videos

Last Updated: Dec 11, 2025

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

2.8K
Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.2K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.1K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine headaches represent a substantial global health burden.
  • Existing pharmaceutical interventions for migraines often yield suboptimal patient outcomes.
  • The calcitonin gene-related peptide (CGRP) pathway is implicated in migraine pathophysiology.

Purpose of the Study:

  • To review the role of CGRP in migraine.
  • To discuss the therapeutic potential of CGRP inhibitors for migraine treatment.

Main Methods:

  • Literature review of studies on CGRP and migraine.
  • Analysis of clinical trial data for CGRP inhibitors.

Main Results:

  • CGRP plays a key role in migraine development and persistence.
  • CGRP inhibitor drugs have demonstrated promising efficacy in clinical trials.
  • These novel therapies offer a new avenue for managing debilitating migraine attacks.

Conclusions:

  • Targeting the CGRP pathway represents a significant advancement in migraine pharmacotherapy.
  • CGRP inhibitors provide a much-needed therapeutic option for patients with difficult-to-treat migraines.